Literature DB >> 18927145

Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology.

A A Gouw1, A Seewann, H Vrenken, W M van der Flier, J M Rozemuller, F Barkhof, P Scheltens, J J G Geurts.   

Abstract

White matter hyperintensities (WMH) are frequently seen on T(2)-weighted MRI scans of elderly subjects with and without Alzheimer's disease. WMH are only weakly and inconsistently associated with cognitive decline, which may be explained by heterogeneity of the underlying neuropathological substrates. The use of quantitative MRI could increase specificity for these neuropathological changes. We assessed whether post-mortem quantitative MRI is able to reflect differences in neuropathological correlates of WMH in tissue samples obtained post-mortem from Alzheimer's disease patients and from non-demented elderly. Thirty-three formalin-fixed, coronal brain slices from 11 Alzheimer's disease patients (mean age: 83 +/- 10 years, eight females) and 15 slices from seven non-demented controls (mean age: 78 +/- 10 years, four females) with WMH were scanned at 1.5 T using qualitative (fluid-attenuated inversion recovery, FLAIR) and quantitative MRI [diffusion tensor imaging (DTI) including estimation of apparent diffusion coefficient (ADC) and fractional anisotropy (FA), and T(1)-relaxation time mapping based on flip-angle array). A total of 104 regions of interest were defined on FLAIR images in WMH and normal appearing white matter (NAWM). Neuropathological examination included (semi-)quantitative assessment of axonal density (Bodian), myelin density (LFB), astrogliosis (GFAP) and microglial activation (HLA-DR). Patient groups (Alzheimer's disease versus controls) and tissue types (WMH versus NAWM) were compared with respect to QMRI and neuropathological measures. Overall, Alzheimer's disease patients had significantly lower FA (P < 0.01) and higher T(1)-values than controls (P = 0.04). WMH showed lower FA (P < 0.01) and higher T(1)-values (P < 0.001) than NAWM in both patient groups. A significant interaction between patient group and tissue type was found for the T(1) measurements, indicating that the difference in T(1)-relaxation time between NAWM and WMH was larger in Alzheimer's disease patients than in non-demented controls. All neuropathological measures showed differences between WMH and NAWM, although the difference in microglial activation was specific for Alzheimer's disease. Multivariate regression models revealed that in Alzheimer's disease, axonal density was an independent determinant of FA, whereas T(1) was independently determined by axonal and myelin density and microglial activation. Quantitative MRI techniques reveal differences in WMH between Alzheimer's disease and non-demented elderly, and are able to reflect the severity of the neuropathological changes involved.

Entities:  

Mesh:

Year:  2008        PMID: 18927145     DOI: 10.1093/brain/awn265

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  109 in total

1.  White matter hyperintensity penumbra.

Authors:  Pauline Maillard; Evan Fletcher; Danielle Harvey; Owen Carmichael; Bruce Reed; Dan Mungas; Charles DeCarli
Journal:  Stroke       Date:  2011-06-02       Impact factor: 7.914

2.  Diagnostic utility of cerebral white matter integrity in early Alzheimer's disease.

Authors:  David K Johnson; Willis Barrow; Raeann Anderson; Amith Harsha; Robyn Honea; William M Brooks; Jeffrey M Burns
Journal:  Int J Neurosci       Date:  2010-08       Impact factor: 2.292

3.  An ex vivo imaging pipeline for producing high-quality and high-resolution diffusion-weighted imaging datasets.

Authors:  Tim B Dyrby; William F C Baaré; Daniel C Alexander; Jacob Jelsing; Ellen Garde; Lise V Søgaard
Journal:  Hum Brain Mapp       Date:  2011-04       Impact factor: 5.038

4.  Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types.

Authors:  H Vrenken; A Seewann; D L Knol; C H Polman; F Barkhof; J J G Geurts
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-22       Impact factor: 3.825

Review 5.  Brain aging, Alzheimer's disease, and mitochondria.

Authors:  Russell H Swerdlow
Journal:  Biochim Biophys Acta       Date:  2011-09-02

6.  Normal-appearing cerebral white matter in healthy adults: mean change over 2 years and individual differences in change.

Authors:  Andrew R Bender; Naftali Raz
Journal:  Neurobiol Aging       Date:  2015-02-11       Impact factor: 4.673

7.  Myelin loss in white matter hyperintensities and normal-appearing white matter of cognitively impaired patients: a quantitative synthetic magnetic resonance imaging study.

Authors:  Mina Park; Yeonsil Moon; Seol-Heui Han; Ho Kyun Kim; Won-Jin Moon
Journal:  Eur Radiol       Date:  2018-11-28       Impact factor: 5.315

8.  An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease.

Authors:  Lidia Sarro; Nirubol Tosakulwong; Christopher G Schwarz; Jonathan Graff-Radford; Scott A Przybelski; Timothy G Lesnick; Samantha M Zuk; Robert I Reid; Mekala R Raman; Bradley F Boeve; Tanis J Ferman; David S Knopman; Giancarlo Comi; Massimo Filippi; Melissa E Murray; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Clifford R Jack; Kejal Kantarci
Journal:  Alzheimers Dement       Date:  2016-08-10       Impact factor: 21.566

9.  Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis.

Authors:  Nikos Gorgoraptis; Claudia A M Wheeler-Kingshott; Thomas M Jenkins; Daniel R Altmann; David H Miller; Alan J Thompson; Olga Ciccarelli
Journal:  Mult Scler       Date:  2010-03-09       Impact factor: 6.312

10.  Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies.

Authors:  Masafumi Ihara; Tuomo M Polvikoski; Ros Hall; Janet Y Slade; Robert H Perry; Arthur E Oakley; Elisabet Englund; John T O'Brien; Paul G Ince; Raj N Kalaria
Journal:  Acta Neuropathol       Date:  2010-01-21       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.